Tudorza Pressair, COPD (Chronic Obstructive Pulmonary Disease)

COPD / The Maher Law Firm / Frank M. EidsonThe FDA (Food and Drug Administration) has approved a new drug to help those with COPD (Chronic Obstructive Pulmonary Disease)

COPD is a progressive disease – meaning it gets worse over time.  Most people who have COPD smoke or used to smoke.  Although, other irritants such as air pollution, chemical fumes, or dust – may contribute to COPD.

COPD makes breathing difficult, it is the fourth leading cause of death in the United States.  Symptoms can include chest tightness, chronic cough, and excessive phlegm.

Those suffering from, Bronchospasm (narrowing of the airways in the lung) associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema have a new drug to help maintain their serious disease.

According to the FDA, “Tudorza Pressair, a dry powder inhaler used twice daily, is a long-acting antimuscarinic agent that helps muscles around the large airways of the lungs stay relaxed to improve airflow.”

“The availability of long-term maintenance drugs for COPD provides additional treatment options for the millions of people who suffer with this debilitating disease.”   Said Curtis Rosenbraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in FDA’s Center for Drug Evaluation and Research.

Tudorza Pressair Side Effects:

  • Paradoxical Bronchospasm
  • Increased Pressure In The Eyes (acute narrow-angle glaucoma)
  • Urinary Retention
  • Headache
  • Inflammation Of The Nasal Passage (nasopharyngitis)
  • Cough

For more information contact The Maher Law Firm or Frank M. Eidson

Bookmark and Share

Comments are closed.